Providing a steady flow of breaking news, analysis, news briefs, document texts and more, all designed to ensure you have the best, most complete information available anywhere about what’s happening in drug pricing.

Merck’s high-profile suit Tuesday alleging HHS’ Medicare drug price negotiation policies are coercive and violate drug makers’ First and Fifth Amendment rights says Congress should have instead empowered HHS to either set a maximum amount the government would pay for covered drugs or to use its natural leverage to obtain more favorable drug prices.

Inside Drug Pricing Home Page

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.